Literature DB >> 30797760

Long-Term Clinical Outcomes of Isolated Ostial Left Anterior Descending Disease Treatment: Ostial Stenting Versus Left Main Cross-Over Stenting.

Gianluca Rigatelli1, Marco Zuin2, Enrico Baracca3, Paola Galasso3, Mauro Carraro3, Alberto Mazza4, Daniela Lanza3, Loris Roncon3, Ramesh Daggubati5.   

Abstract

BACKGROUND: The optimal strategy for treating ostial left anterior descending coronary artery (LAD) disease remains matter of speculation. We evaluated the impact on long-term outcomes of ostial LAD disease treated by means of ostial stenting (the floating-stent) or left main (LM)-to-LAD cross-over stenting.
METHODS: Clinical and instrumental records of 74 consecutive patients with isolated ostial LAD disease, enrolled between the 1st January 2012 and the 1st January 2017 were reviewed. Patients have been stratified according the stenting techniques adopted: ostial stenting (OS) or LM cross-over (CO).
RESULTS: Seventy-four consecutive patients (54 males, mean age 73.39 ± 9.54 years old) have been analyzed. In CO patients the SYNTAX score (16.2 ± 3.3 vs 24.1 ± 2.5, p < 0.0001) and the percentages of rotablation resulted higher than in OS group. IVUS has been predominantly used in CO groups revealing a significant extension of plaque burden of at least 10 mm of LM proximal to the LAD ostium in all the 18 out of 21 patients (85.7%) undergone IVUS-guided procedure. Fluoroscopy time and contrast medium volume were higher in OS versus CO group of patients. On a mean follow-up of 49.7 ± 7.9 months, MACE and target vessel revascularization (TVR) were 21.0% and 21.0% in OS groups versus 10.1 and 5.6% in the CO group (p = 0.20 and p = 0.04, respectively). Restenosis was higher in the OS than in CO group of patients and was located angiographically at the ostium.
CONCLUSIONS: On long-term follow-up CO seems to be superior to OS technique for isolated ostial LAD disease especially in the presence of heavy calcification.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angioplasty; Coronary angiography; Coronary artery disease; Interventional; Surgery

Year:  2019        PMID: 30797760     DOI: 10.1016/j.carrev.2019.01.030

Source DB:  PubMed          Journal:  Cardiovasc Revasc Med        ISSN: 1878-0938


  5 in total

1.  Stentless at ostium: a novel approach for treating ostial left anterior descending or left circumflex coronary artery lesions with drug-coated balloons.

Authors:  Wen-Jie Lu; Liang Pan; Zhan-Ying Han; San-Cong Pan; Xi Wang; Ying-Guang Shan; Meng Peng; Xiao-Fei Qin; Guo-Ju Sun; Pei-Sheng Zhang; Jian-Zeng Dong; Chun-Guang Qiu
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  Feasibility and Safety of Drug-Coated Balloon-Only Angioplasty for De Novo Ostial Lesions of the Left Anterior Descending Artery: Two-Center Retrospective Study.

Authors:  Chuang Li; Xuebo Ding; Lefeng Wang; Kuibao Li; Xinchun Yang; Liping Liu; Li Xu
Journal:  Front Cardiovasc Med       Date:  2022-04-25

3.  Side Branch Late Thrombosis After Left Main Coronary Artery Crossover Stenting.

Authors:  Sultan Alotaibi; Hajo Heyer; Gert Richardt; Abdelhakim Allali
Journal:  Cardiol Ther       Date:  2022-06-30

4.  DCB combined with provisional DES implantation in the treatment of De Novo Medina 0,1,0 or 0,0,1 left main coronary bifurcation lesions: A proof-of-concept study.

Authors:  Emrah Erdoğan; Zheng Li; Yong-Xiang Zhu; Vincenzo Tufaro; Si-Li Feng; Qian Li; Li Liang; Shang Chang; Ling-Tong Bu; Bing Liu; Qi-Hua Zhou; Nathan A L Yap; Christos V Bourantas; Yao-Jun Zhang
Journal:  Anatol J Cardiol       Date:  2022-03       Impact factor: 1.475

5.  Percutaneous coronary intervention for bifurcation coronary lesions: the 15th consensus document from the European Bifurcation Club.

Authors:  Francesco Burzotta; Jens Flensted Lassen; Thierry Lefèvre; Adrian P Banning; Yiannis S Chatzizisis; Thomas William Johnson; Miroslaw Ferenc; Sudhir Rathore; Remo Albiero; Manuel Pan; Olivier Darremont; David Hildick-Smith; Alaide Chieffo; Marco Zimarino; Yves Louvard; Goran Stankovic
Journal:  EuroIntervention       Date:  2021-03-19       Impact factor: 6.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.